Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - An Indian generic drug maker cannot be halted from manufacturing and selling a generic version of Roche's locally patented lung cancer drug Tarceva (erlotinib) in what a spokesman for the Mumbai-based company said was a "landmark" ruling under the country's three-year-old patent regime

You may also be interested in...



Glivec and Tarceva Patent Cases Failed Because Evidence Of Efficacy Overlooked – IP Attorney

Despite industry criticism of India's patent enforcement system, recent IP cases, such as the Tarceva and Glivec cases, have demonstrated India's High Courts' ability to enforce judgments and reach well-reasoned conclusions with relative speed, according to Schiff Hardin attorney Christopher Ohly

Glivec and Tarceva Patent Cases Failed Because Evidence Of Efficacy Overlooked – IP Attorney

Despite industry criticism of India's patent enforcement system, recent IP cases, such as the Tarceva and Glivec cases, have demonstrated India's High Courts' ability to enforce judgments and reach well-reasoned conclusions with relative speed, according to Schiff Hardin attorney Christopher Ohly

Indian Court Restrains Cipla From Exporting Generic Tarceva

NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel